Navigation Links
New Shire Holding Company Proposal
Date:4/16/2008

BASINGSTOKE, England and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- Shire plc ("Shire" or the "Company") (LSE: SHP) (NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that further to yesterday's announcement regarding Shire's new holding company proposal, it will today post the Circular and associated documents to its shareholders. A Prospectus, in relation to the ordinary shares in the new Shire holding company, to be called Shire Limited, has been published and both the Prospectus and Circular have been posted on the Company's website: http://www.shire.com.

Copies of the Circular and Prospectus have been submitted to the UK Listing Authority and are available for inspection at the Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS, tel. +44-20-7066-1000.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire to Introduce a New UK Listed Holding Company
2. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
3. Shire plc: Long Term Incentive Plan
4. Shire plc: IFRS Results for the Year Ending December 31, 2007
5. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
6. Shire plc: Correction Re Website
7. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
8. Shire Engages Palio
9. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... -- STOCKHOLM, August 27, 2010 ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... Massachusetts, August 26, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
... CARY, N.C., Aug. 26 SciQuest, Inc ... procurement and supplier enablement solutions, ... list of the fastest-growing, private companies in America. ... in 2007. (Logo: http://photos.prnewswire.com/prnh/20100624/DA25925LOGO ) ...
Cached Biology Technology:Athera Signs Distribution Agreement in Scandinavia 2Athera Signs Distribution Agreement in Scandinavia 3Athera Signs Distribution Agreement in Scandinavia 4Athera Signs Distribution Agreement in Scandinavia 5Athera Signs Distribution Agreement in Scandinavia 6Athera Signs Distribution Agreement in Scandinavia 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 2Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 3Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 4Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 5Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 6Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 7Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 8Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 9SciQuest Makes the Inc. 500|5000 List of Fastest-Growing Companies for Fourth Consecutive Year 2
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... have sexes, just so-called mating types. A new study ... there are great similarities between the parts of DNA that ... of DNA that determine mating types in certain fungi. ... of the evolutionary development of sex chromosomes. In the ...
... National Lung Cancer Partnership, in partnership with the ... their third annual research grant competition. The ... in basic lung cancer biology, risk assessment, prevention, detection, ... Genentech and our very generous donors, were able to ...
... leading causes of blindnessage-related macular degeneration and diabetic retinopathycan ... a protein found in blood vessel cells, researchers at ... other institutions have announced in a new study. ... when the protein, Robo4, was activated in mice models ...
Cached Biology News:Fungi can tell us about the origin of sex chromosomes 2National Lung Cancer Partnership and LUNGevity Foundation 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 3
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: